Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
Heart failure is a clinical syndrome responsible for at least one-third of hospitalisations amongst cardiac patients, with escalating mortality and healthcare costs on both public and private health care. Both prevalence and incidence of heart failure increase steeply with advancing age, making it a...
Saved in:
Main Authors: | M. O.E. Irhuma, M. Vally |
---|---|
Format: | article |
Language: | EN |
Published: |
AOSIS
2016
|
Subjects: | |
Online Access: | https://doaj.org/article/801839061dbb4212a01f2e4dfd12d184 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
by: Cuthbert JJ, et al.
Published: (2020) -
Reply to Siniorakis et al., “COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure”
by: David S. Fedson, et al.
Published: (2020) -
Recent and Upcoming Drug Therapies for Pediatric Heart Failure
by: Karla L. Loss, et al.
Published: (2021) -
Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
by: Domingo Pascual-Figal, et al.
Published: (2021) -
Effect of Angiotensin–Neprilysin Versus Renin–Angiotensin System Inhibition on Renal Outcomes: A Systematic Review and Meta-Analysis
by: Ying Xu, et al.
Published: (2021)